Top Markets
#1 Derive Derive +36.07%
#2 Cross Cross +18.56%
#3 The Bitcoin Bull The Bitcoin Bull +14.92%
#4 Geodnet Geodnet +10.04%
#5 Gama Token Gama Token +9.18%
#6 Biconomy Biconomy +8.72%
#7 Starpower Starpower +7.90%
#8 Humanity Humanity +7.57%
#9 Steakhouse ETH Morpho Vault Steakhouse ETH Morpho Vault +6.71%
#10 Quantum Resistant Ledger Quantum Resistant Ledger +6.64%
Coin of the day
Derive Derive
Settings
Language
ENGLISH
Currency
USD
Theme
Gemina Laboratories Ltd. Gemina Laboratories Ltd.

Gemina Laboratories Ltd.

GLAB
Rank in Stocks #35861
Gemina Laboratories Ltd. is a Canadian biotechnology company dedicated to the... Gemina Laboratories Ltd. is a Canadian biotechnology company dedicated to the research, development, and commercialization of in-vitro diagnostics. The firm invents innovative surface functionalization chemistries for identifying pathogens and biomarkers. Among its current projects, Gemina is advancing the POC Antigen COVID test, a rapid, point-of-care lateral flow assay strip specifically designed to detect active COVID-19 infections. The company maintains its headquarters in Vancouver, Canada.
Share Price
$0.04377166
Last synced: 2026-02-05
Market Cap
$3.35M
Change (1 day)
-0.30%
Change (1 year)
-87.90%
Country
CA
Trade Gemina Laboratories Ltd. (GLAB)

Category

Healthcare
P/E ratio for Gemina Laboratories Ltd. (GLAB)
P/E ratio as of 2026 TTM: 0
According to Gemina Laboratories Ltd. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Gemina Laboratories Ltd. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 18.38 -
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.